Compare Bristol-Myers Squibb Co (BMY) vs Freeport-McMoRan Inc (FCX) Price & Performance

BMY trades at $64.65, up 1.63% with bullish technical signals and strong fundamentals. The stock shows robust profitability with 18.87% net margin and 46.7% ROE, supported by recent FDA approval for ZENBEXUS therapy and consistent earnings beats. Valuation remains reasonable with P/E of 14.03 and P/S of 2.65. Analyst consensus price target stands at $68.56 with 45% buy ratings.

BMY presents a compelling investment case with strong growth portfolio offsetting patent cliffs, though risks include legal challenges and debt levels. The stock's current valuation and recent positive developments suggest potential upside toward analyst targets, balanced by competitive pressures in the biopharma sector.

FCX trades at $66.83, down 2.98% on the day, but maintains a bullish technical trend with strong analyst support. The company has beaten earnings estimates for three consecutive quarters, with Q3 2026 expected at $0.72 EPS. Revenue remains stable around $25.9B, while net income margin improved to 11.38% in 2026. Recent news highlights operational challenges like lower copper volumes but also growth initiatives at Grasberg and Bagdad.

The outlook is positive with a consensus price target of $73.85, implying ~10% upside. Key opportunities include exposure to high copper prices and expansion projects, while risks involve production volatility, cost pressures, and reliance on commodity cycles. The stock's valuation appears elevated with a P/E of 33.93, requiring sustained earnings growth to justify further gains.